Qualitative Exploration of Engaging Patients as Advisors in a Program of Evidence Synthesis

Cobuilding the Science to Enhance Impact

Jennifer M. Gierisch, PhD, MPH,*† Jaime M. Hughes, PhD, MPH, MSW;‡
John W. Williams Jr, MD, MHSc;*‡ Adelaide M. Gordon, MPH,*
and Karen M. Goldstein, MD, MSPH*‡

Background: There is an increasing expectation for research to involve patient stakeholders. Yet little guidance exists regarding patient-engaged research in evidence synthesis. Embedded in a learning health care system, the Veteran Affairs Evidence Synthesis Program (ESP) provides an ideal environment for exploring patient-engaged research in a program of evidence synthesis.

Objective: The objective of this study was to explore views, barriers, resources, and perceived values of engaging patient advisors in a national program of evidence synthesis research.

Methods: We conducted 10 qualitative interviews with ESP researchers and 2 focus groups with patient stakeholder informants. We queried for challenges to patient involvement, resources needed to overcome barriers, and perceived values of patient engagement. We analyzed qualitative data using applied thematic and matrix techniques.

Results: Patient stakeholders and researchers expressed positive views on the potential role for patient engagement in the Veteran Affairs ESP. Possible contributions included topic prioritization, translating findings for lay audiences, and identifying clinically important outcomes relevant to patients. There were numerous barriers to patient involvement, which were more commonly noted by ESP researchers than by patient stakeholders. Although informants were able to articulate multiple values, we found a lack of clarity around measurable outcomes of patient involvement in systematic reviews.

Conclusions: The research community increasingly seeks patient input. There are many perceived and actual barriers to seeking robust patient engagement in systematic reviews. This study outlines emerging practices that other evidence synthesis programs should consider, such as the careful selection of stakeholders; codeveloped expectations and goals; and adequate training and appropriate resources to ensure meaningful engagement.

Key Words: systematic review, patient engagement, evidence synthesis, public involvement, qualitative

Patients are increasingly valued for their contributions to research as scientific collaborators. Patients’ lived experiences of health conditions can improve research quality and relevance, and accelerate the adoption of findings into practice.¹⁻⁴ Patient input into research design and dissemination has been explored most commonly in health services research and clinical trials.⁵⁻⁶ Notably, the Patient-Centered Outcomes Research Institute (PCORI) advocates engaging patients as stakeholders at multiple levels of trial development and conduct.⁷ However, there has been less focus on how best to engage patients in evidence synthesis.

Patient perspectives can optimize relevance, accessibility, and impact of systematic reviews.⁸⁻⁹ However, evidence synthesis presents slightly different opportunities and challenges to involving patient stakeholders. First, stakeholder involvement in the form of technical expertise is expected in evidence synthesis; yet, compared with other types of stakeholders, patients may offer different value at different stages of research.¹⁰ Second, evidence synthesis involves the collection of data across multiple studies examining the same question, which requires consideration of unfamiliar and highly technical concepts. Although methodologically important, this aspect of systematic reviews removes patient stakeholders from clinical scenarios directly relevant to their lived experience. Third, systematic reviews are often conducted by evidence synthesis scientists who may lack direct or ongoing connection to patients possessing the requisite
Participants. This lack of connection to relevant patient populations may pose a barrier to timely identification of patient stakeholders. Although patients have contributed to systematic reviews for 2 decades, little practical guidance about how best to involve patient perspectives in systematic reviews exists, and there is little work on patient engagement in organizations that conduct systematic reviews.

The Veteran Affairs (VA) national Evidence Synthesis Program (ESP) consists of a coordinating center and 4 geographically dispersed hubs. Embedded within a learning health care system, each hub generates at least 3 evidence syntheses annually in response to clinical and policy questions nominated by national VA offices. ESP products are routinely used to guide clinical and programmatic decisions on the local and national levels. In addition, each ESP project convenes a technical expert panel comprising both VA and non-VA national topical experts to provide input and feedback about protocol development and interpretation of findings. Thus, ESP clearly mandates stakeholder—although not specifically patient stakeholder—involvement. Further, some ESP hubs are colocated within VA research centers that have convened patient research advisory councils, called Veteran Engagement Groups (VEGs). VEGs include veterans and veteran caregivers who advise investigators on research. This structure presents unique opportunities for investigating perceptions about patients as collaborators in a national program of evidence synthesis research. Thus, we sought to explore views of systematic review researchers, patients, and caregivers on how to integrate patient stakeholders into a national evidence synthesis program.

METHODS

Design

We conducted and analyzed semi-structured qualitative interviews with ESP leaders (ie, directors, associate directors) and programmatic staff, and focus group discussions (FGDs) with established VEGs of patient stakeholders. As the primary goal of our evaluation was to inform ESP quality improvement efforts, this work was designated as a nonresearch operations project.

Participants

We purposively sampled key informants across 4 ESP hubs and the coordinating center. To solicit input from different positions within ESP, we sampled across organizational roles (eg, directors, research assistants). Key informants were recruited via e-mail. Interviews took place in July and August 2018. We conducted FGDs with established groups of veteran patients and caregivers. To identify participants, we contacted the faculty at ESP-affiliated VA research centers and asked if we could conduct FGDs with their veteran groups. The FGDs took place in August 2018.

Approach

To develop interview and FGD guides, we conducted a rapid scan of the peer-reviewed literature in Medline from inception to March 2018. The search yielded 2249 citations of which we retained 8 reports.8–15 A single investigator reviewed citations for studies of any design that addressed patient involvement in systematic review science. We developed narrative summaries of key findings of the identified reports and used these summaries to construct a list of common themes. We used these themes as domains from which to construct discussion guides (Table 1).

All individual key informant interviews were conducted via telephone by 2 investigators with qualitative expertise (J.M.G., J.M.H.). Because this project was conducted to inform ESP process improvement, we chose an approach that provided high quality and timely information on quality improvement. Thus, rather than record interviews and transcribe them, we used other approaches to optimize rigor.16–18 One investigator took real-time detailed field notes focusing on verbatim statements during interviews and captured respondent input via structured interview summary templates. To ensure accuracy, we used several member-checking techniques19,20 to assess the validity of the data and findings, such as having a subset of key informants review their interview summaries for completeness and presenting key findings to informants for further clarification and validation. We aimed to conduct at least 12 interviews unless we reached thematic saturation before that threshold.21

Before starting FGDs, we conducted a brief overview of ESP and systematic review methods, assuming participants had little prior knowledge of evidence synthesis (Fig. 1). The FGDs were held in person and conducted by trained qualitative researchers (J.M.G., J.M.H.). For similar reasons as noted above, we did not record FGDs. We captured detailed notes in structured templates and circulated them to FGD participants to verify accuracy and completeness. Following prior work on sample size and thematic saturation, we aimed to conduct 3 FGDs but only conducted 2 due to time and logistical constraints.22

We conducted an applied thematic analysis using both a priori codes structured from interview guides and emergent codes to develop a codebook.23 Two investigators (J.M.G., J.M.H.) applied codes to 2 interviews and 1 FGD summary. Codes were compared, a coding scheme was finalized through discussion, and then the coding scheme was applied to all notes by 1 team member (J.M.G.) using NVivo software (version 12, 2018; QSR International Pty Ltd). For data reduction, we used matrix analysis and categorized themes by key informant type (ie, patient/caregiver, ESP hub or coordinating center leadership, ESP staff) to compare findings.24 Before analysis, we redacted personal identifiers from summaries to protect informants’ identities.

RESULTS

We invited 3 individuals at each of the 4 hub sites plus 3 additional participants from the coordinating center for a total of 15 potential participants. Ten individuals agreed to participate (5 ESP leaders, 5 ESP staff), representing each hub and coordinating center. Experience with ESP ranged from ≤1 to 10 years. We also conducted 2 FGDs with VEGs. Reflecting the overall VA population, most VEG members were male (73%), white (81%), and served during the Vietnam War era (63%).

We organized our findings around interview guide domains: (1) potential roles for patient collaborators in an evidence synthesis program; (2) perceived barriers; (3) resources needed to overcome barriers; and (4) value of involving patient collaborators and how to measure that impact.
TABLE 1. Focus Group Discussion Guide and Individual Interview Guide

| Topics                               | Example Questions                                                                 | Topics                               | Example Questions                                                                 |
|--------------------------------------|------------------------------------------------------------------------------------|--------------------------------------|------------------------------------------------------------------------------------|
| Prior knowledge                      | Did you have prior knowledge of the ESP at the VA?                                 | Types of stakeholders                | What types of stakeholders do you typically engage within the systematic review process? |
| Perceived value                      | What do you think are the value of these reports?                                 | Collaborate with veterans/care partners at the national and local ESP level | What are your thoughts about how we could collaborate with veterans and their care partners at the national ESP program level? |
| Collaborate with veterans/care partners at the national and local ESP level | What are your thoughts about being a collaborator at the national ESP program level? What are your thoughts about patients/care partners as collaborators for individual reviews conducted at the ESP sites? |
| How do you see veterans/care partners being involved in individual systematic reviews? | Value of involving patients                                                        | Value of involving patients          | What value do you see in involving veterans/care partners in the ESP program and systematic review science? |
| Value of Involving patients          | What value do you see in involving veterans/care partners in the ESP program and systematic review science? For researchers, what do you think is the gain for engaging with patients/care partners? | Barriers                             | What challenges or barriers do you see in having veterans/care partners involved in the conduct of systematic reviews? What do you need to overcome these? |
| Barriers                             | What challenges or barriers do you see in having veterans/care partners involved in the conduct of systematic reviews? What do you need to overcome these? | Patient preparation needed           | What type of preparation would one need on systematic reviews or training before feeling like you could contribute to the systematic review research process? |
| Patient preparation needed           | What type of preparation would one need on systematic reviews or training before feeling like you could contribute to the systematic review research process? | Recruitment                          | How would we recruit veterans/care partners to be collaborators? |
| Recruitment                          | How would we recruit veterans/care partners to be collaborators?                  | Loss by not engaging                 | What do you think is lost by not engaging veterans/care partners in the science of systematic reviews? |
| Loss by not engaging                 | What do you think is lost by not engaging veterans/care partners in the science of systematic reviews? | Main impacts                         | What are the main impacts of involving veterans/care partners in systematic reviews? |
| Main impacts                         | What do you see as the main impacts of involving veteran patients/care partners in systematic reviews? What would this change? | Dissemination of results             | How might veterans/care partners wish to be involved in project results? |
| How might veterans/care partners wish to be involved in project results?      | Measure the impact                                                                 | Crowdsourcing                        | What are your thoughts on enlisting veterans/care partners in helping with some of the microtasks associated with systematic reviews that could be done quickly and with little preparation or training? |
| Crowdsourcing                        | What are your thoughts on enlisting veterans/care partners in helping with some of the microtasks associated with systematic reviews that could be done quickly and with little preparation or training? |

Under each domain, we focused first on areas of concordance and then explored differences in themes by key informant type (ie, ESP staff, ESP leader, patient/caregivers). When warranted, we also explored how findings differed at the national ESP programmatic level and individual study level.

Patients’ Roles in ESP

Theme Concordance

Table 2 provides a matrix of potential patient roles in systematic reviews by key informant type. All stakeholder groups agreed that prioritizing topics for consideration at the national level was an area ripe for patient contribution. As 1 patient stated, “We are VERY INTERESTED in helping think through what is important to study.” There was high concordance between patients and researchers’ opinions regarding the central role patients could play in helping ESP contextualize, translate, and disseminate findings on individual evidence synthesis studies. Suggested ideas included disseminating findings through patient networks and social media, integrating patient narratives into evidence reports to contextualize findings, or having patients codevelop plain-language briefs. As one patient representative stated, “In plain talk … KISS … ‘keep it simple, stupid’ … we are mediators of simple, plain talk. We could do this for reviews.”

Patient Theme Differences

Patients were willing to take on additional responsibilities and eager to be more deeply involved in reviews. Some expressed wanting to serve as coinvestigators, help screen citations, or interpret findings based on their lived experience. Patients recognized the potential limitations of
their contributions due to the methodological focus of systematic review science. Moreover, patient and caregiver FGD members expressed a high degree of interest in nominating topics to be considered for ESP reviews. Patients proposed an online portal to garner solicitations from a broad base of patients and caregivers.

Research Staff and Leaders Theme Differences

The ESP research staff and leadership were more reluctant to open the nomination process to patients and others outside VA clinical operations due to 2 main concerns: (1) not having capacity at the national programmatic level to vet and prioritize additional nominations; and (2) needing to continue to demonstrate impact on the VA’s learning health care system. ESP researchers described having a ready consumer of their evidence reports because topics are nominated by operations and clinical stakeholders and represent pressing information needs with direct clinical and policy relevance. Researchers saw the optimal role of patients as strategic advisors, providing feedback on key, isolated aspects of reviews, such as outcome selection, and functioning similarly to technical expert panel members. As 1 ESP researcher stated, “picking outcomes that matter and clinically important effects … Patients could help with that.”

Barriers to Engaging Patients in ESP

TABLE 3. Perceived barriers to Patient Engagement in the Evidence Synthesis Program by Key Informant Type

| Perceived Barriers                  | Research Leaders | Research Staff | Patients and Caregivers |
|-------------------------------------|------------------|----------------|-------------------------|
| Slows down timelines                | X                | X              |                         |
| Logistically difficult due to short timelines | X                | X              |                         |
| Not enough personnel                | X                | X              |                         |
| Identifying interested patients     | X                | X              |                         |
| Unclear research ethics oversight   | X                | X              |                         |
| Managing patient collaborator       |                  |                |                         |
| expectations                        |                  |                |                         |
| High costs                          |                  |                |                         |
| Managing potential bias             | X                |                |                         |
| Not enough time to contribute       |                  |                | X                       |
| Unwillingness of researchers to collaborate |                  |                |                         |
| Mistrust of research                |                  |                |                         |
| Lack of representativeness of patients |                  |                | X                       |

X indicates theme expressed by informant type.

Patient Theme Differences

Compared with ESP informants, patients identified far fewer barriers to engagement and endorsed time constraints to make meaningful contributions, perceived unwillingness of researchers to collaborate with patients, and patients’ historical mistrust of research as patient-specific barriers to engagement.

TABLE 2. Thoughts on Patient Role in the Evidence Synthesis Program by Key Informant Type

| Patient Roles                  | Researchers* | Patients and Caregivers |
|--------------------------------|--------------|-------------------------|
| Identify and nominate topics   | X            |                         |
| Refine topics                  | X            |                         |
| Prioritize topics              | X            | X                       |
| Serve as coinvestigator        | X            |                         |
| Screen title and abstracts     | X            |                         |
| Abstract data                  | X            |                         |
| Provide strategic guidance     | X            | X                       |
| Contextualize findings         | X            | X                       |
| Translate findings             | X            | X                       |
| Dissemination of findings      | X            |                         |

*Researchers = Evidence Synthesis Program directors, associate directors, and research staff such as program managers, research assistants.

X indicates theme expressed by informant type.
Research Staff and Leaders Theme Differences

ESP staff and leaders identified more barriers to patient involvement than did FGD patients and caregivers. When looking across barrier type, ESP staff defined barriers primarily related to timelines and logistics that would influence daily project operations. Research staff identified the inadequate time to engage patients in fast-paced project timelines, insufficient personnel to coordinate patient-engagement efforts, and logistical challenges in identifying patients, and uncertainty about research ethics oversight of patient involvement.

ESP leaders also identified these challenges but contributed additional barriers. They expressed concerns related to managing patient collaborator expectations and high potential costs (eg, staff time, patient compensation) associated with patient involvement. However, ESP leaders most often noted the need to manage potential bias that patients might bring to the process, explaining that it might be difficult for patients to remain objective when speaking from personal experience. As one researcher stated, “They [patients] can have VERY STRONG opinions that can be hard to manage … I have some trepidation because of this.”

Values of Patient Engagement

All informants articulated the perceived value of patient involvement. Values clustered into 3 areas of value to patient, organization, and science (Table 4), but there was low concordance across informant type. Yet, all informant had difficulty articulating key outcomes of patient engagement and ideas on measuring patient-engagement value.

| TABLE 4. Perceived Values of Patient Engagement in the Evidence Synthesis Program by Key Informant Type |
|---------------------------------------------------------------|
| Perceived Values                                              | Informant Type |
|                                                              | Research Leaders | Research Staff | Patients and Caregivers |
| Unclear value of patient engagement                           | X               | X             |
| Value to patients                                             | X               | X             |
| Patients learn about systematic reviews                        | X               |               |
| Giving back to others                                         | X               | X             |
| Improving health care by informing clinical policy             | X               |               |
| Value to organization                                         | X               |               |
| Better understanding of the impact of work                     | X               |               |
| Promotes organization’s mission                                | X               | X             |
| Value to science                                               | X               |               |
| Enhances the credibility of the science                        |                  |
| Provide exposure to effective models of patient engagement     | X               |               |
| Improve the quality of the science                             | X               | X             |
| Increases relevance of science                                 | X               | X             |
| Increase the impact of science                                 | X               | X             |
| Speeds dissemination of findings                               | X               | X             |
| Creates champions for science and change                       | X               | X             |
| X indicates theme expressed by informant type.                  |
Facilitating Capacity

ESP informants expressed that establishing processes to facilitate the capacity to produce meaningful patient engagement was essential. Clear guidance on research ethics rules was seen as crucial to fostering the capacity to engage patient collaborators. ESP informants expressed needing procedures for identifying, vetting, and training patient collaborators. Ideas for identifying patient collaborators included partnering with veteran service organizations or disease advocacy groups, requesting use of established patient advisory groups, or asking frontline providers to nominate patients. Regardless of how patients were identified, ESP informants expressed a need for patient collaborators who had some understanding of systematic review methodology to foster authentic engagement. One ESP informant noted, “You do not want to make paraprofessionals but you want them to feel comfortable and prepared.” Last, ESP informants wanted guidance on how and when to engage patients in research to foster meaningful engagement. One ESP informant stated, “Do it with real intention…gain buy-in from local centers, develop process.”

CONCLUSIONS

We found that patient stakeholders and researchers alike expressed positive views on patient engagement in VA ESP. Potential contributions included assisting with topic prioritization, translating findings for lay audiences, and identifying clinically important outcomes relevant to patients. Barriers to patient involvement were primarily raised by research key informants rather than patient/caregivers. Evidence synthesis research teams cited concerns about time and financial costs required for meaningful patient involvement on tight project timelines. In addition, while informants were able to articulate multiple values, we found a lack of clarity around measurable outcomes of patient involvement in systematic reviews.

Much of the existing information about patient engagement with systematic review organizations has been generated by Cochrane, who is committed to partnering with patients.9 The 2018 Cochrane Colloquium was a “Patients Included” event organized around “Cochrane for all—better evidence for better health decisions.”25 Through Cochrane, patients have primarily been engaged as referees for specific reviews and during translation of report findings to plain-language summaries.9 Although we found interest in similar types of activities among patients and caregivers, they were also eager to be involved in task-oriented project activities. Our ESP research informants had significant concerns about how to do this in a sustainable and meaningful way. Cochrane has recently expanded opportunities for patients to engage in methods activities of reviews by inviting them to perform key steps such as citation screening.26 Other innovations are likely needed, such as software platforms for topic prioritization, to engage patients in systematic review processes in a meaningful yet cost-effective manner.

A novel finding from our work is the potential role for patients in earlier topic prioritization stages, which has not been commonly explored. Within the VA health care system, veteran input is highly valued, as exemplified by the widespread promotion of patient advisory groups within VA research centers to inform research activities. The veterans in our FGD felt they could offer added value in providing input around topic prioritization, whereas researchers raised concerns about the need for careful planning and weighing of input at this stage to avoid introducing bias. Balancing stakeholder input is not unique to patient stakeholders and has been a recognized challenge for other types of stakeholder involvement.13

Although researchers agree that patient input can aid evidence synthesis, measuring the success of patient involvement in systematic reviews requires clarification. Researcher informants hesitated to involve patients in program activities without clear directives on metrics to evaluate effectiveness, echoing a previously noted9,11 need for a delineated approach to assess impact. Potential domains for such assessment include relevance, accessibility, transparency, and research uptake.10

Researcher informants universally noted concerns over the additional resources entailed to conduct meaningful patient engagement. Specifically, there was a concern that increasing patient involvement in earlier stages of topic nomination and prioritization could raise demands and expectations for more products without the necessary growth in resources. This is a legitimate concern for ESP given fixed budgets and relatively inflexible timelines. The resource burden of patient engagement in evidence synthesis has been noted previously and includes time and financial resources.9,13,27 The importance of maintaining longitudinal relationships with patient stakeholders for optimal partnering is one example of this burden. Moreover, there is a need for clear guidance on optimal ways to engage with patients, including staff training on interactions with patient stakeholders, how to identify appropriate individuals, and how to manage potential perceptions of the impact on scientific integrity.9,23 PCORI, grappling with similar challenges, has developed training programs for patient peer reviewers and resources to support investigators in patient engagement. These types of resources may be adapted to facilitate patient engagement in systematic review programs.

The VA ESP constitutes an ideal site for building evidence on patient-engaged research in systematic reviews. The ESP is a national program with 4 geographically dispersed hubs colocated within VA health services research centers, 3 of which have patient advisory groups. This structure offers a unique opportunity to test strategies and construct the evidence base on optimally engaging patients as advisors in a program of systematic review research. Opportunities exist within the ESP to pilot strategies, such as a partnership with existing patient advisory panels to cobuild plans for patient engagement in systematic reviews, which can be tested and refined.

Our study had several strengths, including multiple sources of data from patient FGD and individual interviews with both ESP staff and senior leaders across different sites, interview guides informed by the literature, a team approach to interviews, use of field notes in the form of interview summaries, and rigorous member checking. Despite these strengths, we note some limitations based on our design choices. First, we opted to not record interviews and FGDs. There are many valid reasons why recordings may not be feasible or necessary. Yet, not recording may open studies up

www.lww-medicalcare.com | S251
to informant social desirability bias and researcher confirmatory bias.16,18,25 We tried to limit these by presenting questions in a neutral format, having someone external to the organization conduct the interviews, and implementing systematic and transparent coding processes facilitated by the state-of-the-science qualitative data analysis software. Next, our sample size was relatively small and not all targeted ESP researchers and patient advisory panels responded to our interview invitation request. We attempted to counteract any resulting potential bias by purposively sampling across the 4 centers. Finally, the results presented here should be interpreted cautiously as they only reflect opinions from one evidence synthesis program.

Early engagement of diverse stakeholders increases the likelihood that end-products will be relevant and useful to decision-makers, provides real-world context for evidence application, and can enhance end-user uptake.2,3,29 There is an increasing expectation for research to involve patient stakeholders. Thus, a shift toward patient engagement in the ESP, and other evidence synthesis programs is likely. There are many perceived and actual barriers to seeking robust patient engagement in systematic reviews. Our study provides information on emerging practices that other evidence synthesis programs need to consider when approaching how to foster patient engagement. Patient and research informants largely agreed that careful selection of stakeholders is critical. All parties should collaboratively outline goals, roles, and expectations. Research staff should provide adequate training and ensure appropriate resources, including patient-engagement expertise, to ensure meaningful engagement. Ongoing evaluation of engagement efforts is needed to assess the value this brings to both science and patient collaborators. Pilot testing and evaluating patient engagement may offer additional insights into processes, metrics, and outcomes. The considerations we report may serve as a foundation for building practical guidance about overcoming barriers to involving patients as meaningful collaborators in systematic review science.

REFERENCES

1. Esmail L, Moore E, Rein A. Evaluating patient and stakeholder engagement in research: moving from theory to practice. J Comp Eff Res. 2015;4:133–145.
2. Graham ID, Logan J, Harrison MB, et al. Lost in knowledge translation: time for a map? J Contin Educ Health Prof. 2006;26:13–24.
3. Keown K, Van Eerd D, Irvin E. Stakeholder engagement opportunities in systematic reviews: knowledge transfer for policy and practice. J Contin Educ Health Prof. 2008;28:67–72.
4. O’Mara-Eves A, Bruntog G, Oliver S, et al. The effectiveness of community engagement in public health interventions for disadvantaged groups: a meta-analysis. BMC Public Health. 2015;15:129.
5. Collins SP, Levy PD, Holl JL, et al. Incorporating patient and caregiver experiences into cardiovascular clinical trial design. JAMA Cardiol. 2017;2:1263–1269.
6. Domecq JP, Prutsky G, Elrafaya T, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89.
7. Frank L, Basch E, Selhy JV. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312:1513–1514.
8. Coman DH, White CM. Discerning the Perception and Impact of Patients Involved in Evidence-based Practice Center Key Informant Interviews. Rockville, MD: Agency for Healthcare Research and Quality; 2017.
9. Morley RF, Norman G, Goldner S, et al. A systematic scoping review of the evidence for consumer involvement in organisations undertaking systematic reviews: focus on Cochrane. Res Involv Engagem. 2016;2:56.
10. Cottrell E, Whitlock E, Kato E, et al. Defining the Benefits of Stakeholder Engagement in Systematic Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
11. Concannon TW, Fuster M, Saunders T, et al. A systematic review of stakeholder engagement in comparative effectiveness and patient-centered outcomes research. J Gen Intern Med. 2014;29:1692–1701.
12. Harris J, Croot L, Thompson J, et al. How stakeholder participation can contribute to systematic reviews of complex interventions. J Epidemiol Community Health. 2016;70:207–214.
13. O’Haire C, McPheeters M, Nakamoto E, et al. Engaging Stakeholders to Identify and Prioritize Future Research Needs. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
14. Pollock A, Campbell P, Baer G, et al. User involvement in a Cochrane systematic review: using structured methods to enhance the clinical relevance, usefulness and usability of a systematic review update. Syst Rev. 2015;4:55.
15. Pollock A, Campbell P, Struthers C, et al. Stakeholder involvement in systematic reviews: a protocol for a systematic review of methods, outcomes and effects. Res Involv Engagem. 2017;3:9.
16. Bachiochi PD, Weisner SP. Qualitative data collection and analysis. In: Rogellberg SG, ed. Handbook of Research Methods in Industrial and Organizational Psychology. Oxford, UK: Blackwell; 2004:161–183.
17. Gale RC, Wu J, Erhardt T, et al. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci. 2019;14:11.
18. Halcomb EJ, Davidson PM. Is verbatim transcription of interview data always necessary? Appl Nurs Res. 2006;19:38–42.
19. Birt L, Scott S, Cavers D, et al. Member checking: a tool to enhance trustworthiness or merely a nod to validation? Qual Health Res. 2016;26:1802–1811.
20. Morse JM. Critical analysis of strategies for determining rigor in qualitative inquiry. Qual Health Res. 2015;25:1212–1222.
21. Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59–82.
22. Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2016;29:3–22.
23. Guest G, MacQueen K, Namey E. Applied Thematic Analysis. Thousand Oaks, CA: Sage Publications; 2012.
24. Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Thousand Oaks, CA: Sage Publications; 2012.
25. Cochrane. Edinburgh Colloquium 2018: round-up; 2019. Available at: www.cochrane.org/news/edinburgh-colloquium-2018-round. Accessed January 11, 2018.
26. Noel-Storr A, Dooley G, Glenville J, et al. The Embase project 2: Crowdsourcing Citation Screening Filtering the Information Overload for better decisions Abstracts of the 23rd Cochrane Colloquium. Vienna, Austria: John Wiley & Sons; 2015.
27. Pollock A, Campbell P, Struthers C, et al. Stakeholder involvement in systematic reviews: a scoping review. Syst Rev. 2018;7:208.
28. Al-Yateem N. The effect of interview recording on quality of data obtained: a methodological reflection. Nurse Res. 2012;19:31–35.
29. Whitlock EP, Lopez SA, Chang S, et al. AHRQ series paper 3: identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63:491–501.